원저 : Troglitazone이 비만증 및 인슐린비의존형 당뇨병 환자 골격근 배양세포의 당원합성효소 활성에 미치는 영향
Year: 1997
Type: article
Abstract: Background: Skeletal muscle is the principal tissue of insulin resistance in obese and non-insulin depen- dent diabetic(NIDDM) subjects. Troglitazone, a mem- ber of thiazolidinedione class of compounds, has been shown to improve glucose tolerance in insulin resi- stant state. At the cellular level, troglitazone has been shown to improve insulin action in skeletal muscle, liver and adipose tissue. However, there has been no direct assessment of mechanism of this drug in insulin resistant human skeletal muscle from obese and obese NIDDM subjects. Methods: To determine the effect of troglitzone on skeletal muscle glycogen synthase(GS) activity in insulin resistant human skeletal muscle, muscle cul- tures from 7 obese non-diabetic and 8 obese NIDDM subjects were grown for 4 weeks and then fused for 4 days either with or without troglitzone(0~5ug/mL) and harvested for GS activity and protein measurement. GS activity was measured by enzy- matic method and protein expression was measured by Western blot using polyclonal antibody specific for C-terminal end of GS protein, Results: Troglitzone increased GS activity(GS activity at 0.1 mM G6P and fractional velocity) dose- dependently in both obese non-diabetic and type II diabetes and the increased GS activity by troglitzone was mostly basal rather than insulin-stimulated. Basal fractional velocity of GS increased 2.8+-0.7 and 3.7 +-1.2 fold in obese non-diabetic and type II diabetes respectively. There was no changes in GS total activity and GS protein expression in either group with troglitzone treatment.. Conclusion: Troglitazone has effects to improve glycogen synthase activity in skeletal tnuscle of obese and obese NIDDM subjects.
Source: Diabetes & Metabolism Journal
Language: Korean
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $500
OpenAlex ID: W3167145386